Physician profile
David J Dunch
NPI 1457339376
$1,730.51
in general payments reported to CMS, 2019-2025
16 companies · $55.05 in 2025
The $55.05 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $140 · 2021: $271 · 2022: $268 · 2023: $299 · 2024: $490 · 2025: $55.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $401.69 | 2019-2024 | Rebyota, Clenpiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.06 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $208.31 | 2022-2024 | Viberzi, Linzess |
| Braintree Laboratories, INC. | $189.54 | 2019-2025 | Suflave, Sutab |
| Medtronic, INC. | $132.91 | 2022 | |
| Celgene Corporation | $91.11 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $81.21 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $48.10 | 2023-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $47.66 | 2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $46.74 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.82 | 2024 | Entyvio |
| Janssen Biotech, INC. | $35.72 | 2023-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $32.95 | 2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $19.50 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $14.55 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.64 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dunch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.